MCF10DCIS.com Xenograft Model of Human Comedo Ductal Carcinoma In Situ
Top Cited Papers
Open Access
- 19 July 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 92 (14), 1185a-1186
- https://doi.org/10.1093/jnci/92.14.1185a
Abstract
Ductal carcinoma in situ (DCIS) is becoming increasingly common, accounting for 25%–30% of newly diagnosed cases of breast cancer (1). The comedo type represents about 40% of the cases and carries the worst prognosis (2). The subsequent incidence of recurrence in patients presenting previously with comedo DCIS was 20% compared with 5% for noncomedo DCIS in one study (3). National Surgical Adjuvant Breast and Bowel Project Protocol B-17 reported a 40% incidence of ipsilateral breast cancer after lumpectomy of comedo DCIS and found that comedo necrosis is the only important predictor for recurrence after lumpectomy (4).Keywords
This publication has 6 references indexed in Scilit:
- Consensus Conference on the Classification of Ductal Carcinoma of the Breast, April 22-25, 1999Cancer, 2000
- Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17Cancer, 1999
- A prognostic index for ductal carcinoma in situ of the breastCancer, 1996
- Xenograft Model of Progressive Human Proliferative Breast DiseaseJNCI Journal of the National Cancer Institute, 1993
- Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation correlation of pathologic parameters with outcome of treatmentCancer, 1993